Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: IMP005
MIFTS: 55

Impotence

Categories: Mental diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Impotence

About this section

MalaCards integrated aliases for Impotence:

Name: Impotence 12 29 55 15
Erectile Dysfunction 12 55 43 73
Erectile Dysfunction Adverse Event 73
Sexual Impotence 12

Classifications:

MalaCards categories:
Anatomical: Mental diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:1875
Sources

Summaries for Impotence

About this section
MedlinePlus : 43 Erectile dysfunction (ED) is a common type of male sexual dysfunction. It is when a man has trouble getting or keeping an erection. ED becomes more common as you get older. But it's not a natural part of aging. Some people have trouble speaking with their doctors about sex. But if you have ED, you should tell your doctor. ED can be a sign of health problems. It may mean your blood vessels are clogged. It may mean you have nerve damage from diabetes. If you don't see your doctor, these problems will go untreated. Your doctor can offer several new treatments for ED. For many men, the answer is as simple as taking a pill. Getting more exercise, losing weight, or stopping smoking may also help. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Impotence, also known as erectile dysfunction, is related to vasculogenic impotence and hyperprolactinemia, and has symptoms including angina pectoris, pelvic pain and tremor. An important gene associated with Impotence is NOS1 (Nitric Oxide Synthase 1), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and Platelet homeostasis. The drugs Methyltestosterone and Testosterone have been mentioned in the context of this disorder. Affiliated tissues include prostate, spinal cord and endothelial, and related phenotypes are normal and reproductive system

Wikipedia : 76 Erectile dysfunction (ED), also known as impotence, is a type of sexual dysfunction characterized by the... more...

Sources

Related Diseases for Impotence

About this section

Diseases related to Impotence via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 104)
# Related Disease Score Top Affiliating Genes
1 vasculogenic impotence 33.6 ALDH7A1 NOS3 PDE5A
2 hyperprolactinemia 30.5 PRL SHBG VIP
3 gynecomastia 30.5 KLK3 PRL SHBG
4 varicocele 29.9 NOS2 NOS3 PRL SHBG
5 vascular disease 29.3 EDN1 KNG1 NOS2 NOS3
6 diabetic neuropathy 11.2
7 amyloidosis, hereditary, transthyretin-related 10.9
8 neuropathy, hereditary sensory and autonomic, type iii 10.9
9 empty sella syndrome 10.9
10 autonomic dysfunction 10.9
11 dysautonomia 10.9
12 multiple system atrophy with orthostatic hypotension 10.9
13 platelet membrane fluidity 10.7 NOS2 NOS3
14 cluster headache 10.6 NOS1 VIP
15 psychosexual disorder 10.6 PDE5A SHBG
16 tetrahydrobiopterin deficiency 10.6 NOS1 NOS3 PRL
17 malignant secondary hypertension 10.6 EDN1 KNG1
18 androgenic alopecia 10.6 KLK3 PRL SHBG
19 peyronie disease 10.6 NOS2 PDE5A
20 diffuse scleroderma 10.5 EDN1 KNG1
21 reproductive system disease 10.5 KLK3 PRL SHBG
22 breast disease 10.5 KLK3 PRL SHBG
23 acute chest syndrome 10.4 EDN1 NOS1 NOS3
24 coronary artery vasospasm 10.4 EDN1 KNG1 NOS3
25 acquired metabolic disease 10.4 NOS3 PRL SHBG
26 renovascular hypertension 10.4 EDN1 NOS1 NOS3
27 persistent fetal circulation syndrome 10.4 EDN1 NOS3 PDE5A
28 ischemic optic neuropathy 10.4 EDN1 NOS3 PDE5A
29 nonarteritic anterior ischemic optic neuropathy 10.3 EDN1 NOS3 PDE5A
30 arteries, anomalies of 10.3 EDN1 KNG1 NOS3
31 chronic mountain sickness 10.3 EDN1 NOS3
32 eisenmenger syndrome 10.3 EDN1 VIP
33 hepatopulmonary syndrome 10.3 EDN1 NOS2 NOS3
34 prostatitis 10.2
35 orthostatic intolerance 10.2 EDN1 NOS2 NOS3
36 jejunoileitis 10.2 ALDH7A1 NOS1 NOS3
37 androgen insensitivity, partial 10.2 SHBG SRD5A1
38 prostate cancer 10.1
39 raynaud phenomenon 10.1 EDN1 PDE5A
40 retinitis pigmentosa 19 10.1 ALDH7A1 KCNMA1
41 prostatic adenoma 10.1 KLK3 SHBG SRD5A1
42 peyronie's disease 10.1
43 urethritis 10.1
44 infertility 10.1
45 alopecia, androgenetic, 1 10.1 SHBG SRD5A1
46 diabetes mellitus 10.0
47 coronary artery anomaly 10.0 EDN1 KNG1 NOS3 PDE5A
48 ischemia 10.0 EDN1 KNG1 NOS2 NOS3
49 aging 9.9
50 priapism 9.9

Graphical network of the top 20 diseases related to Impotence:



Diseases related to Impotence
Sources

Symptoms & Phenotypes for Impotence

About this section

UMLS symptoms related to Impotence:


angina pectoris, pelvic pain, tremor, symptom/complaint potency (excluding p07 p08), equilibration disorder, inability to maintain erection, unable to perform sex

MGI Mouse Phenotypes related to Impotence:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 normal MP:0002873 9.56 ALDH7A1 EDN1 NOS1 NOS3 PDE3A SEPT3
2 reproductive system MP:0005389 9.23 NOS2 NOS3 PDE3A PRL SRD5A1 VIP
Sources

Drugs & Therapeutics for Impotence

About this section

Drugs for Impotence (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 304)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methyltestosterone Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-18-4 6010
2
Testosterone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-22-0 6013
3
Testosterone enanthate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 315-37-7 9416
4
Testosterone undecanoate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 5949-44-0
5
Benzocaine Approved, Investigational Phase 4,Phase 3 1994-09-7, 94-09-7 2337
6
Nebivolol Approved, Investigational Phase 4,Not Applicable 152520-56-4, 99200-09-6, 118457-14-0 71301
7
Tadalafil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 171596-29-5 110635
8
Fenofibrate Approved Phase 4,Phase 3 49562-28-9 3339
9
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
10
Felodipine Approved, Investigational Phase 4 72509-76-3 3333
11
Irbesartan Approved, Investigational Phase 4 138402-11-6 3749
12
Metoprolol Approved, Investigational Phase 4,Phase 3,Not Applicable 37350-58-6, 51384-51-1 4171
13
Dutasteride Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 164656-23-9 152945 6918296
14
Alprostadil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 745-65-3 149351 5280723
15
Nitric Oxide Approved Phase 4 10102-43-9 145068 160954
16
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492
17
Zinc Approved, Investigational Phase 4 7440-66-6 23994
18
Curcumin Approved, Investigational Phase 4 458-37-7 969516
19
Yohimbine Approved, Investigational, Vet_approved Phase 4 146-48-5 8969
20
Hydrochlorothiazide Approved, Vet_approved Phase 4,Phase 3 58-93-5 3639
21
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
22
Tiagabine Approved, Investigational Phase 4 115103-54-3 60648
23
AT-101 Approved, Investigational Phase 4 90141-22-3, 652-67-5 12597
24
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
25
Isosorbide Dinitrate Approved, Investigational Phase 4 87-33-2 6883
26
Nadolol Approved Phase 4 42200-33-9 39147
27
Magnesium oxide Approved Phase 4 1309-48-4 14792
28
Udenafil Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 268203-93-6 6918523
29
Tamsulosin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 106133-20-4 129211
30
Eszopiclone Approved, Investigational Phase 4 138729-47-2 969472
31
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
32
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
33
Xylometazoline Approved, Investigational Phase 4 526-36-3 5709
34
Candesartan cilexetil Approved Phase 4 145040-37-5 2540
35
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 1 50-28-2 5757
36 Estradiol valerate Approved, Investigational, Vet_approved Phase 4,Phase 1 979-32-8
37
Polyestradiol phosphate Approved Phase 4,Phase 1 28014-46-2
38
Rosiglitazone Approved, Investigational Phase 4,Phase 1 122320-73-4 77999
39
Selegiline Approved, Investigational, Vet_approved Phase 4 14611-51-9 26757 5195
40
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
41 tannic acid Approved, Nutraceutical Phase 4,Phase 3
42
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 77-92-9 311
43
Allantoin Approved, Nutraceutical Phase 4 97-59-6 204
44
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
45 Orange Approved, Nutraceutical Phase 4
46
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
47
N,N-dimethylarginine Experimental Phase 4 30315-93-6 123831
48
Candesartan Experimental Phase 4 139481-59-7 2541
49
2,4-thiazolidinedione Investigational Phase 4 2295-31-0
50 Anabolic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 587)
# Name Status NCT ID Phase Drugs
1 Treatment of Erectile Dysfunction in Hypogonadal Men With Testosterone Undecanoate Unknown status NCT00555087 Phase 4 Testosterone Undecanoate and/or PDE-5
2 A Study to Evaluate the Efficacy and Safety of Vardenafil in Men With Erectile Dysfunction Caused by Spinal Cord Injury Unknown status NCT00725790 Phase 4 Vardenafil;Placebo
3 Effect of Vardenafil on Erectile Dysfunction and Portal Hemodynamics in Patients With Liver Cirrhosis Unknown status NCT02344823 Phase 4 Vardenafil;Placebo intake once daily
4 Nebivolol Effects on Endothelial Function and Erectile Function Unknown status NCT01885988 Phase 4 Nebivolol;Sugar Pill
5 Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer Unknown status NCT00906269 Phase 4 Sildenafil therapy plus post-NSRRP HBO2T;Sildenafil therapy plus sham post-NSRRP HBO2T
6 Safety and Clinical Effectiveness of 2 Lower Dose Combined PDE5i's vs. Single Maximal Dose PDE5i Unknown status NCT00498680 Phase 4 Sildenafil, Vardenafil;Sildenafil;Vardenafil;Sildenafil & Vardenafil
7 Evaluation of Safety and Effectiveness of 2 Lower Dose Combined PDE5i's Versus Single Maximal Dose PDE5i Treatment Unknown status NCT01364701 Phase 4 Sildenafil 100 mg;Tadalafil 20 mg;Combination half of maximal dose for sildenafil & tadalafil
8 Effect of Sildenafil on Quality of Sexual Life in Mild to Normally Sexually Functioning Males Unknown status NCT00313898 Phase 4 sildenafil (viagra)
9 Effect of Testosterone on Endothelial Function and Microcirculation in Type 2 Diabetic Patients With Hypogonadism Unknown status NCT01084369 Phase 4 Testosterone
10 Treatment of Hyperlipidemia and Sexual Dysfunction Unknown status NCT00923676 Phase 4 fenofibrate;Rosuvastatin;fenofibrate + rosuvastatin
11 Combined Antihypertensive Therapy and Sexual Dysfunction Unknown status NCT01238705 Phase 4 Felodipine add Irbesartan;Felodipine add Metoprolol
12 A Study in Patients With Erectile Dysfunction Completed NCT01122264 Phase 4 Tadalafil;Sildenafil Citrate
13 Impact Of Viagra On Sexual Satisfaction Of Men With Mild Erectile Dysfunction Who Are Sexually Dissatisfied Completed NCT00301262 Phase 4 Viagra (Sildenafil citrate)
14 Evaluation of LEVITRA to Advance the Treatment of Erectile Dysfunction Completed NCT00664833 Phase 4
15 L-Arginine and Erectile Dysfunction Completed NCT00777075 Phase 4 L-arginine;Placebo
16 Effect of Tadalafil on the Quality of Life and Sexual Life in Erectile Dysfunction Completed NCT00422578 Phase 4 tadalafil
17 Investigate the Responsiveness of the Erectile Quality Scale to Vardenafil Flexible Dose vs Placebo in Males With Erectile Dysfunction (ED) Completed NCT00665340 Phase 4 Placebo;Levitra (Vardenafil, BAY38-9456)
18 Vardenafil and Cognitive-behavioral Sex Therapy for the Treatment of Erectile Dysfunction (STEDOV) Completed NCT02450188 Phase 4 Vardenafil
19 Evaluating of the Efficacy and Safety of Vardenafil in Subjects With Erectile Dysfunction Completed NCT00662441 Phase 4 Levitra (Vardenafil, BAY38-9456)
20 Assessing Efficacy and Safety of Flexible Dosing With Vardenafil in Subjects With Erectile Dysfunction and Hyperlipidemia Completed NCT00663845 Phase 4 Levitra (Vardenafil, BAY38-9456);Placebo
21 Assessment of Vardenafil in Patients With Erectile Dysfunction in Asia Completed NCT00668135 Phase 4 Vardenafil (Levitra, BAY38-9456);Placebo
22 Evaluation of the Safety and Efficacy of Vardenafil in Subjects With Erectile Dysfunction Completed NCT00681772 Phase 4 Levitra (Vardenafil, BAY38-9456)
23 Satisfaction, Confidence and Naturalness in Men With Psychogenic Erectile Dysfunction (ED) Completed NCT01153204 Phase 4 Sildenafil citrate
24 Mild To Moderate Erectile Dysfunction Study Completed NCT00137072 Phase 4 Viagra (Sildenafil Citrate) 100 mg
25 Efficacy and Safety of Lodenafil Carbonate in the Treatment of Erectile Dysfunction in Patients With Diabetes. Completed NCT01180283 Phase 4 lodenafil carbonate
26 Study Of Men With Mild To Moderate Erectile Dysfunction To Evaluate The Efficacy Of Viagra 8 Hours Post-Dose Completed NCT00143260 Phase 4 Viagra (Sildenafil Citrate) 100 mg
27 BAY38-9456, 5/10/20mg, vs.Placebo in Erectile Dysfunction Completed NCT00665054 Phase 4 Levitra (Vardenafil, BAY38-9456);Placebo
28 A Study of Tadalafil and Sildenafil in Men With Erectile Dysfunction in China Completed NCT01352507 Phase 4 Tadalafil;Sildenafil
29 Use of Sildenafil (Viagra) in Diabetic Men With Erectile Dysfunction: the Impact on Blood Vessels Completed NCT00199563 Phase 4 Viagra
30 Evaluation of Efficacy and Safety of Vardenafil in Patients With Erectile Dysfunction and Type 1 Diabetes Completed NCT00660998 Phase 4 Levitra (Vardenafil, BAY38-9456);Placebo
31 Study of Vardenafil in Patients Suffering From Erectile Dysfunction and Metabolic Syndrome Completed NCT00738400 Phase 4 Vardenafil (Levitra, BAY38-9456);Placebo
32 A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy Completed NCT00106392 Phase 4 Tacrolimus;Placebo
33 The Therapy of Nebido as Mono or in Combination With PDE-5 Inhibitors in Hypogonadal Patients With Erectile Dysfunction Completed NCT00421460 Phase 4 Testosterone Undecanoate,1000mg
34 A Study Evaluating Vardenafil Compared to Placebo in Subjects With Erectile Dysfunction (ED) and Dyslipidemia Completed NCT00379756 Phase 4 LEVITRA (vardenafil);placebo
35 Research Evaluating a PDE5 Inhibitor for Erectile Dysfunction Completed NCT01698684 Phase 4 Placebo;Avanafil 100 mg;Avanafil 200 mg
36 A Study of Tadalafil (LY450190) in Chinese Men With Erectile Dysfunction Completed NCT02224846 Phase 4 Tadalafil
37 QEQ Treatment Responsiveness Evaluation Study Completed NCT00151463 Phase 4 sildenafil citrate
38 Quality of Erection Study Completed NCT00159900 Phase 4 Sildenafil Citrate
39 Evaluating the Efficacy Vardenafil 10 mg vs Tadalafil 10 mg in in Subjects With Erectile Dysfunction (ED) Completed NCT00663130 Phase 4 Levitra (Vardenafil, BAY38-9456);Tadalafil
40 A Multicenter, Randomized, Parallel Group, Double-Blind, Placebo Controlled, Flexible Dose Escalation Study To Evaluate Sexual And Relationship Satisfaction In The Female Partner Of Men With Erectile Dysfunction Treated With Sildenafil Citrate Completed NCT00644631 Phase 4 sildenafil;placebo
41 Effect of Testosterone in Men With Erectile Dysfunction Completed NCT00512707 Phase 4 Sildenafil citrate (open label);Testosterone gel
42 A Multicenter, Open Label, To Evaluate The Efficacy And Satisfaction Of Patrex® In Men With Erectile Dysfunction. Completed NCT00468650 Phase 4 sildenafil citrate
43 Effects of Sildenafil on Penile Vascular Function in Hypertensive Men With Erectile Dysfunction Completed NCT02620995 Phase 4 sildenafil citrate
44 A Randomized, Open-Label, Crossover, Multicenter, Single Dose Comparator Study Evaluating Onset Of Penile Rigidity In Men With Erectile Dysfunction Who Are Treated With Sildenafil And Tadalafil Completed NCT00644956 Phase 4 tadalafil;sildenafil
45 A Study Of The Safety and Efficacy Of Viagra In Men With Erectile Dysfunction Who Do Not Self Identify. Completed NCT00343200 Phase 4 Placebo;Viagra (sildenafil citrate)
46 Exploratory CSII Trial on Erectile Dysfunction in T2DM Patients Completed NCT01468519 Phase 4 Insulin;Insulin
47 Efficacy Study Measuring The Impact Of Treatment With Viagra On The Depressive Symptoms Of Men With Erectile Dysfunction Completed NCT00159809 Phase 4 Viagra (Sildenafil citrate)
48 A Study Evaluating the Efficacy and Safety of Sildenafil in Patients With Erectile Dysfunction Receiving Hemodialysis Completed NCT00654017 Phase 4 placebo;sildenafil
49 Evaluating the Efficacy of Vardenafil in Subjects With Erectile Dysfunction (ED) Administered 12, 18 or 24 Hours Prior to Intercourse Completed NCT00667979 Phase 4 Levitra (Vardenafil, BAY38-9456);Placebo
50 A Randomised Study of Levitra to Treat Men With Erections Problems and Previously Untreated With Similar Therapy. Completed NCT00668096 Phase 4 Levitra (Vardenafil, BAY38-9456);Placebo

Search NIH Clinical Center for Impotence

Inferred drug relations via UMLS 73 / NDF-RT 51 :
Sources

Genetic Tests for Impotence

About this section

Genetic tests related to Impotence:

# Genetic test Affiliating Genes
1 Impotence 29
Sources

Anatomical Context for Impotence

About this section

MalaCards organs/tissues related to Impotence:

41
Prostate, Spinal Cord, Endothelial, Bone, Testes, Kidney, Heart
Sources

Publications for Impotence

About this section

Articles related to Impotence:

(show top 50) (show all 1177)
# Title Authors Year
1
Newly Diagnosed Bipolar Disorder and the Subsequent Risk of Erectile Dysfunction: A Nationwide Cohort Study. ( 29425665 )
2018
2
Large Solitary Plexiform Neurofibroma of the Penis Without Erectile Dysfunction: a Case Report from Kerala. ( 29581693 )
2018
3
A case of pheochromocytoma with negative MIBG scintigraphy, PET-CT and genetic tests (VHL included) and a rare case of post-operative erectile dysfunction. ( 29860716 )
2018
4
Tadalafil 5 mg Once Daily Improves Lower Urinary Tract Symptoms and Erectile Dysfunction: A Systematic Review and Meta-analysis. ( 29341503 )
2018
5
Penile sensory thresholds in subtypes of premature ejaculation: implications of comorbid erectile dysfunction. ( 29405168 )
2018
6
The relationship between penile deformity, age, psychological bother, and erectile dysfunction in a sample of men with Peyronie's Disease (PD). ( 29795530 )
2018
7
Antiplatelet (aspirin) therapy as a new option in the treatment of vasculogenic erectile dysfunction: a prospective randomized double-blind placebo-controlled study. ( 29344879 )
2018
8
Erectile dysfunction in cirrhosis is impacted by liver dysfunction, portal hypertension, diabetes and arterial hypertension. ( 29368385 )
2018
9
A Novel Noninvasive Ultrasound Vibro-elastography Technique for Assessing Patients With Erectile Dysfunction and Peyronie Disease. ( 29548864 )
2018
10
Malleable Penile Implant Is an Effective Therapeutic Option in Men With Peyronie's Disease and Erectile Dysfunction. ( 29336942 )
2018
11
Erectile dysfunction is associated with subclinical carotid vascular disease in young men lacking widely-known risk factors. ( 29442076 )
2018
12
The Magic Pill: The Branding of Impotence and the Positioning of Viagra as Its Solution through Edutainment. ( 29436964 )
2018
13
Re: Extracorporeal Shock Wave Therapy (ESWT) in Urology: A Systematic Review of Outcome in Peyronie's Disease, Erectile Dysfunction, and Chronic Pelvic Pain. ( 29449032 )
2018
14
Adipose-Derived Stem Cell-Derived Exosomes Ameliorate Erectile Dysfunction in a Rat Model of Type 2 Diabetes. ( 28781215 )
2017
15
A Variant in the Precursor of MicroRNA-146a is Responsible for Development of Erectile Dysfunction in Patients with Chronic Prostatitis via Targeting NOS1. ( 28218896 )
2017
16
Significance of serum endothelial cell specific molecule-1 (Endocan) level in patients with erectile dysfunction: a pilot study. ( 28424502 )
2017
17
Potent Phosphodiesterase Inhibition and Nitric Oxide Release Stimulation of Anti-Impotence Thai Medicinal Plants from "MANOSROI III" Database. ( 28811831 )
2017
18
Correlation of Subjective Symptoms in Patients with Benign Prostatic Hyperplasia and Erectile Dysfunction. ( 28428671 )
2017
19
Impotence Following Radical Prostatectomy: Insight into Etiology and Prevention. ( 28012765 )
2017
20
Persistent erectile dysfunction in men exposed to the 5I+-reductase inhibitors, finasteride, or dutasteride. ( 28289563 )
2017
21
The combination of penile revascularization surgery with penile corrective techniques as an alternative to prosthesis implantation in patients with peyronie's disease accompanied by erectile dysfunction: Long-term results. ( 29255189 )
2017
22
A novel experimental model of erectile dysfunction in rats with heart failure using volume overload. ( 29095897 )
2017
23
Early weight loss predicts the reduction of obesity in men with erectile dysfunction and hypogonadism undergoing long-term testosterone replacement therapy. ( 28084147 )
2017
24
Re: Subclinical Vascular Disease and Subsequent Erectile Dysfunction: The Multiethnic Study of Atherosclerosis (MESA). ( 29370615 )
2017
25
Association of endothelial nitric oxide synthase polymorphisms with an increased risk of erectile dysfunction. ( 26908069 )
2017
26
Factors Associated With Erectile Dysfunction and the Peyronie's Disease Questionnaire in Patients With Peyronie Disease. ( 28554517 )
2017
27
History of erectile dysfunction as a predictor of poor physical performance after an acute myocardial infarction. ( 28067536 )
2017
28
Measurement of electrochemical conductance of penile skin using Sudoscan(Ar): A new tool to assess neurogenic impotence. ( 28528745 )
2017
29
Re: Factors Associated with Erectile Dysfunction and the Peyronie's Disease Questionnaire in Patients with Peyronie Disease. ( 29144914 )
2017
30
Erectile Dysfunction in Male Adults With Atopic Dermatitis and Psoriasis. ( 28109691 )
2017
31
Impotence after Radical Prostatectomy. ( 28010984 )
2017
32
Aberrant baseline brain activity in psychogenic erectile dysfunction patients: a resting state fMRI study. ( 29243122 )
2017
33
Erectile Dysfunction Agents and Nonarteritic Anterior Ischemic Optic Neuropathy. ( 27886893 )
2017
34
Does any association exist between Chronic Obstructive Pulmonary Disease and Erectile Dysfunction? The DECODED study. ( 28624321 )
2017
35
Erectile dysfunction and the risk of prostate cancer. ( 28881762 )
2017
36
Functional Variations in the NOS3 Gene Are Associated With Erectile Dysfunction Susceptibility, Age of Onset and Severity in a Han Chinese Population. ( 28268155 )
2017
37
Associations of VEGF Gene Polymorphisms With Erectile Dysfunction and Related Risk Factors. ( 28364978 )
2017
38
Omnipotence and Impotence: The Need for Conversation When Patients and Clinicians Disagree. ( 27366844 )
2016
39
Efficacy and safety of phosphodieterase-5 inhibitors for treatment of erectile dysfunction secondary to spinal cord injury: a systemic review and meta-analysis. ( 26882490 )
2016
40
Safety and Potential Effect of a Single Intracavernous Injection of Autologous Adipose-Derived Regenerative Cells in Patients with Erectile Dysfunction Following Radical Prostatectomy: An Open-Label Phase I Clinical Trial. ( 27077129 )
2016
41
Quality analysis of randomized controlled trials in the International Journal of Impotence Research: quality assessment and relevant clinical impact. ( 27904149 )
2016
42
Risk of erectile dysfunction associated with use of 5-I+ reductase inhibitors for benign prostatic hyperplasia or alopecia: population based studies using the Clinical Practice Research Datalink. ( 27659058 )
2016
43
Are Erectile Dysfunction Medications Causally Related to Nonarteritic Anterior Ischemic Optic Neuropathy? ( 26828844 )
2016
44
Infertility, impotence, and emasculation - psychosocial contexts for abandoning reproduction. ( 26924280 )
2016
45
Increased subsequent risk of erectile dysfunction among middle and old age males with chronic osteomyelitis: a nationwide population-based cohort study. ( 27169492 )
2016
46
Hypogonadism and erectile dysfunction as harbingers of systemic disease. ( 27141446 )
2016
47
Association between Gout and Erectile Dysfunction: A Systematic Review and Meta-Analysis. ( 28036397 )
2016
48
Study of the relationship between male erectile dysfunction and type 2 diabetes mellitus/metabolic syndrome and its components. ( 27036148 )
2016
49
Impact of prostate volume on erectile dysfunction and premature ejaculation. ( 27145693 )
2016
50
Nocturia and prevalence of erectile dysfunction in Japanese patients with type 2 diabetes mellitus: The Dogo Study. ( 27180646 )
2016
Sources

Variations for Impotence

About this section
Sources

Expression for Impotence

About this section
Search GEO for disease gene expression data for Impotence.
Sources

Pathways for Impotence

About this section

Pathways related to Impotence according to GeneCards Suite gene sharing:

(show all 13)
# Super pathways Score Top Affiliating Genes
1
Response to elevated platelet cytosolic Ca2+ 66
Show member pathways
 13.12 KCNMA1 KNG1 NOS1 NOS2 NOS3 PDE3A
2
Platelet homeostasis 66
Show member pathways
 12.01 KCNMA1 NOS1 NOS2 NOS3 PDE3A PDE5A
3
Apelin signaling pathway 37
11.84 NOS1 NOS2 NOS3
4
HIF-1 signaling pathway 37
11.69 EDN1 NOS2 NOS3
5
Mechanisms of CFTR activation by S-nitrosoglutathione (normal and CF) 22
Show member pathways
 11.42 NOS1 NOS2 NOS3
6
Arginine and proline metabolism 37
Show member pathways
 11.31 ALDH7A1 ARG2 NOS1 NOS2 NOS3
7
Doxorubicin Pathway, Pharmacokinetics 61
Show member pathways
 11.23 NOS1 NOS2 NOS3
8
Ibuprofen Pathway, Pharmacodynamics 61
11.06 NOS1 NOS2 NOS3
9
Arginine biosynthesis 37
Show member pathways
 11.04 ARG2 NOS1 NOS2 NOS3
10
Doxorubicin Pathway (Cardiomyocyte Cell), Pharmacodynamics 61
10.96 NOS1 NOS2 NOS3
11
Nitric oxide stimulates guanylate cyclase 66
Show member pathways
 10.72 KCNMA1 NOS1 NOS2 NOS3 PDE3A PDE5A
12
Effects of Nitric Oxide 1
10.45 NOS1 NOS2 NOS3
13
NO-dependent CFTR activation (normal and CF) 22
10.37 NOS1 NOS2 NOS3 PDE5A
Sources

GO Terms for Impotence

About this section

Cellular components related to Impotence according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell division site GO:0032153 9.37 SEPT3 SEPT6
2 septin filament array GO:0032160 9.32 SEPT3 SEPT6
3 septin complex GO:0031105 9.26 SEPT3 SEPT6
4 septin ring GO:0005940 9.16 SEPT3 SEPT6
5 caveola GO:0005901 9.13 KCNMA1 NOS1 NOS3
6 vesicle membrane GO:0012506 8.8 NOS1 NOS2 NOS3

Biological processes related to Impotence according to GeneCards Suite gene sharing:

(show all 26)
# Name GO ID Score Top Affiliating Genes
1 response to lipopolysaccharide GO:0032496 9.84 EDN1 NOS1 NOS2 NOS3
2 response to hypoxia GO:0001666 9.76 EDN1 KCNMA1 NOS1 NOS2
3 cell redox homeostasis GO:0045454 9.74 NOS1 NOS2 NOS3
4 response to hormone GO:0009725 9.72 NOS1 NOS2 NOS3
5 exogenous drug catabolic process GO:0042738 9.63 CYP3A4 NOS1
6 positive regulation of cardiac muscle hypertrophy GO:0010613 9.62 EDN1 PDE5A
7 regulation of sodium ion transport GO:0002028 9.62 NOS1 NOS3
8 androgen metabolic process GO:0008209 9.61 CYP3A4 SRD5A1
9 septin ring assembly GO:0000921 9.61 SEPT3 SEPT6
10 negative regulation of blood pressure GO:0045776 9.61 NOS1 NOS2 NOS3
11 negative regulation of blood coagulation GO:0030195 9.6 EDN1 KNG1
12 negative regulation of calcium ion transport GO:0051926 9.59 NOS1 NOS3
13 negative regulation of potassium ion transport GO:0043267 9.58 NOS1 NOS3
14 body fluid secretion GO:0007589 9.58 EDN1 VIP
15 negative regulation of hydrolase activity GO:0051346 9.56 NOS1 NOS3
16 vasodilation GO:0042311 9.54 KNG1 NOS1 NOS3
17 regulation of systemic arterial blood pressure by endothelin GO:0003100 9.51 EDN1 NOS3
18 nitric oxide mediated signal transduction GO:0007263 9.5 NOS1 NOS2 NOS3
19 diterpenoid metabolic process GO:0016101 9.49 PDE3A SRD5A1
20 peptidyl-cysteine S-nitrosylation GO:0018119 9.48 NOS1 NOS2
21 positive regulation of guanylate cyclase activity GO:0031284 9.43 NOS1 NOS2 NOS3
22 positive regulation of oocyte development GO:0060282 9.4 PDE3A PDE5A
23 arginine catabolic process GO:0006527 9.33 NOS1 NOS2 NOS3
24 regulation of blood vessel size GO:0050880 9.26 EDN1 KNG1 NOS1 NOS3
25 nitric oxide biosynthetic process GO:0006809 8.92 ARG2 NOS1 NOS2 NOS3
26 oxidation-reduction process GO:0055114 10 ALDH7A1 CYP3A4 NOS1 NOS2 NOS3 SRD5A1

Molecular functions related to Impotence according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 oxidoreductase activity GO:0016491 9.91 ALDH7A1 CYP3A4 NOS1 NOS2 NOS3 SRD5A1
2 iron ion binding GO:0005506 9.78 CYP3A4 NOS1 NOS2 NOS3
3 heme binding GO:0020037 9.76 CYP3A4 NOS1 NOS2 NOS3
4 hormone activity GO:0005179 9.71 EDN1 PRL VIP
5 flavin adenine dinucleotide binding GO:0050660 9.69 NOS1 NOS2 NOS3
6 NADP binding GO:0050661 9.58 NOS1 NOS2 NOS3
7 3,5-cyclic-nucleotide phosphodiesterase activity GO:0004114 9.55 PDE3A PDE5A
8 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, NAD(P)H as one donor, and incorporation of one atom of oxygen GO:0016709 9.54 NOS1 NOS2 NOS3
9 3,5-cyclic-GMP phosphodiesterase activity GO:0047555 9.52 PDE3A PDE5A
10 FMN binding GO:0010181 9.5 NOS1 NOS2 NOS3
11 cadmium ion binding GO:0046870 9.49 NOS1 NOS3
12 arginine binding GO:0034618 9.43 NOS1 NOS2 NOS3
13 NADPH-hemoprotein reductase activity GO:0003958 9.33 NOS1 NOS2 NOS3
14 tetrahydrobiopterin binding GO:0034617 9.13 NOS1 NOS2 NOS3
15 nitric-oxide synthase activity GO:0004517 8.8 NOS1 NOS2 NOS3
Sources

Sources for Impotence

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....